| |
CTTN (n = 174)
|
RhoA (n = 205)
|
ROCK (n = 202)
|
CLDN-1 (n = 206)
|
CLDN-2 (n = 110)
|
CLDN-4 (n = 206)
|
|---|
|
Total population
|
|
CTTN
|
1
| | | | | |
|
RhoA
|
0.065 (0.395)*
|
1
| | | | |
|
ROCK
|
0.170 (0.028)
|
0.246 (< 0.001)
|
1
| | | |
|
CLDN-1
|
− 0.036 (0.646)
|
− 0.007 (0.917)
|
− 0.062 (0.391)
|
1
| | |
|
CLDN-2
|
0.043 (0.686)
|
− 0.017 (0.866)
|
0.237 (0.014)
|
0.034 (0.727)
|
1
| |
|
CLDN-4
|
0.013 (0.868)
|
0.086 (0.228)
|
− 0.023 (0.752)
|
0.411 (< 0.001)
|
− 0.102 (0.292)
|
1
|
|
ER- and PR ± (n = 23)
|
|
CTTN
|
1
| | | | | |
|
RhoA
|
0.182 (0.465)
|
1
| | | | |
|
ROCK
|
0.398 (0.091)
|
0.397 (0.067)
|
1
| | | |
|
CLDN-1
|
0.198 (0.415)
|
0.009 (0.967)
|
− 0.049 (0.832)
|
1
| | |
|
CLDN-2
|
0.655 (0.029)
|
− 0.247 (0.465)
|
− 0.285 (0.396)
|
− 0.316 (0.344)
|
1
| |
|
CLDN-4
|
− 0.027 (0.914)
|
0.077 (0.748)
|
0.007 (0.975)
|
0.095 (0.691)
|
− 0.366 (0.299)
|
1
|
|
ER + and PR ± (n = 158)
|
|
CTTN
|
1
| | | | | |
|
RhoA
|
0.074 (0.404)
|
1
| | | | |
|
ROCK
|
0.128 (0.153)
|
0.280 (0.001)
|
1
| | | |
|
CLDN-1
|
-0.065 (0.469)
|
− 0.001 (0.994)
|
− 0.066 (0.433)
|
1
| | |
|
CLDN-2
|
0.033 (0.786)
|
− 0.005 (0.965)
|
0.267 (0.016)
|
0.020 (0.858)
|
1
| |
|
CLDN-4
|
0.016 (0.859)
|
0.086 (0.301)
|
− 0.015 (0.862)
|
0.451 (< 0.001)
|
− 0.119 (0.284)
|
1
|
|
ALNM– (n = 64)
| | | | | | |
|
CTTN
|
1
| | | | | |
|
RhoA
|
− 0.056 (0.705)
|
1
| | | | |
|
ROCK
|
− 0.049 (0.741)
|
0.233 (0.083)
|
1
| | | |
|
CLDN-1
|
0.070 (0.638)
|
0.011 (0.932)
|
− 0.166 (0.217)
|
1
| | |
|
CLDN-2
|
− 0.041 (0.847)
|
0.166 (0.382)
|
0.733 (< 0.001)
|
− 0.045 (0.810)
|
1
| |
|
CLDN-4
|
0.022 (0.882)
|
0.103 (0.446)
|
− 0.194 (0.151)
|
0.522 (< 0.001)
|
− 0.131 (0.490)
|
1
|
|
ALNM + (n = 120)
|
|
CTTN
|
1
| | | | | |
|
RhoA
|
0.129 (0.204)
|
1
| | | | |
|
ROCK
|
0.226 (0.027)
|
0.311 (0.001)
|
1
| | | |
|
CLDN-1
|
− 0.079 (0.448)
|
− 0.010 (0.921)
|
0.040 (0.681)
|
1
| | |
|
CLDN-2
|
0.121 (0.384)
|
− 0.160 (0.219)
|
− 0.098 (0.443)
|
0.004 (0.976)
|
1
| |
|
CLDN-4
|
0.030 (0.769)
|
0.068 (0.479)
|
0.029 (0.763)
|
0.377 (< 0.001)
|
− 0.028 (0.826)
|
1
|
|
Stage I (n = 55)
|
|
CTTN
|
1
| | | | | |
|
RhoA
|
0.060 (0.710)
|
1
| | | | |
|
ROCK
|
0.519 (0.001)
|
0.252 (0.077)
|
1
| | | |
|
CLDN-1
|
− 0.025 (0.877)
|
− 0.060 (0.674)
|
− 0.115 (0.422)
|
1
| | |
|
CLDN-2
|
− 0.064 (0.766)
|
0.204 (0.298)
|
0.741 (< 0.001)
|
− 0.049 (0.800)
|
1
| |
|
CLDN-4
|
0.232 (0.144)
|
0.039 (0.758)
|
0.002 (0.990)
|
0.389 (0.004)
|
− 0.136 (0.480)
|
1
|
|
Stages II-III (n = 126)
|
|
CTTN
|
1
| | | | | |
|
RhoA
|
0.098 (0.329)
|
1
| | | | |
|
ROCK
|
0.069 (0.496)
|
0.308 (0.001)
|
1
| | | |
|
CLDN-1
|
0.002 (0.980)
|
0.022 (0.818)
|
0.002 (0.987)
|
1
| | |
|
CLDN-2
|
0.130 (0.359)
|
− 0.163 (0.213)
|
− 0.130 (0.324)
|
0.013 (0.923)
|
1
| |
|
CLDN-4
|
− 0.052 (0.609)
|
0.085 (0.375)
|
− 0.019 (0.842)
|
0.429 (< 0.001)
|
− 0.014 (0.917)
|
1
|
- The statistically significant finding is shown in italics (P < 0.05)
- N number, CTTN cortactin, RhoA ras homolog gene family member A, ROCK rho-associated kinase, CLDN claudin, ER estrogen receptor, PR progesterone receptor, ALNM axillary lymph node metastasis
- *Data were expressed as standardized β coefficient (P-value)
